Use of PD ‐1 inhibitor tislelizumab in the treatment of advanced pulmonary sarcomatoid carcinoma: A case report-Reference-Cited by-同舟云学术

Use of PD ‐1 inhibitor tislelizumab in the treatment of advanced pulmonary sarcomatoid carcinoma: A case report

Published:2021-12-24 Issue:3 Volume:13 Page:502-505
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Xu Li¹,Tao Ning‐ning¹^ORCID,Liang Bin¹,Li Dao‐wei¹,Li Huai‐chen¹²^ORCID,Su Li‐li¹

Affiliation:

1. Department of Respiratory and Critical Care Medicine Shandong Provincial Hospital Affiliated to Shandong University, Shandong Provincial Hospital Affiliated to Shandong First Medical University Jinan Shandong China

2. College of Traditional Chinese Medicine Shandong University of Traditional Chinese Medicine Jinan Shandong China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14290

Reference17 articles.

1. Pulmonary sarcomatoid carcinoma: an analysis of a rare cancer from the Surveillance, Epidemiology, and End Results database†

2. Efficacy of First-Line Chemotherapy in Patients with Advanced Lung Sarcomatoid Carcinoma

3. Pulmonary sarcomatoid carcinoma: progress, treatment and expectations

4. Survival Analysis and Prediction Model for Pulmonary Sarcomatoid Carcinoma Based on SEER Database

5. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sintilimab combined with anlotinib as first-line treatment for advanced sarcomatoid carcinoma of head and neck: a case report and literature review;Frontiers in Oncology;2024-04-24

2. A case report: A new promising treatment for pulmonary sarcomatoid carcinoma - Tislelizumab and Anlotinib combined with local radiotherapy;Heliyon;2023-11

3. Survival analysis and nomogram for pulmonary sarcomatoid carcinoma: an SEER analysis and external validation;BMJ Open;2023-10

4. Targeted therapy for rare lung cancers: Status, challenges, and prospects;Molecular Therapy;2023-07

5. Survival outcomes and prognostic factors of lung cancer patients with the MET exon 14 skipping mutation: A single-center real-world study;Frontiers in Oncology;2023-03-09